- Our Services
-
Patients and Families
- Get Directions
- Parking
- Childrens Locations
- Getting Around
- Guidelines for Visitors
- Contact a Patient
- Contact Children's
- Send an e-Card
- Gift Shop
Planning a Visit
- Find a Doctor
- Child Health A-Z
- Community Ed.Classes
- Injury Prevention
- International Patients
- Medical Records
- Patient Handbook
- Patient Procedures
Parents
- For Health Professionals
- Research
- Ways to Give
-
News
-
Adding Breast Milk Ingredient to Formula Could Prevent Deadly Intestinal Problem in Premature Babies
-
Children's Holds Groundbreaking Ceremony for Expansion to New South Fayette Location
-
Child Neurodevelopmental and Mental Health Disabilities on the Rise, Study Finds
News Releases
-
Research
Crohn’s Disease - Risk and Microbial Marker Study
Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children with Crohn’s Disease
Protocol Description
The purpose of this study is to identify “bio-markers” easily found in blood, stool or in the lining of the intestines that can help doctors understand which children with Crohn’s Disease are at risk of developing complications quickly, enabling them to better treat patients.
Eligibility Criteria
Subject to certain exclusion criteria, boys and girls up to age 16 who have newly diagnosed or suspected Inflammatory bowel disease, also known as Crohn’s disease, ulcerative colitis or indeterminate colitis, will be asked to participate in the study.
Males: Up to age 16
Females: Up to age 16
Requirements
During the initial visit, researchers will collect medical history information as well as blood and stool samples for analysis. Blood draws will also be done at the 3 annual follow-up visits. For patients scheduled for a routine colonoscopy with biopsy, there is a study option to collect a few additional biopsies for research purposes.
Visits: 4
Duration: 3 years
Status: Open for Enrollment
Source(s) of Support
Crohn’s and Colitis Foundation of America
Additional Information
Study Description at National Institutes of Health
Primary Investigator(s)
David J. Keljo, MD, PhD
Contact Information
For information or to enroll, please contact
Sandra L. McRandal, MSN, CRNP
412-692-5180
Last Update
July 28, 2011
July 28, 2011
